Cross-Talk Between Nitrosative Stress, Inflammation and Hypoxia-Inducible Factor in Patients with Adrenal Masses

Barbara Choromańska¹
Piotr Myśliwiec¹
Tomasz Kozłowski¹
Magdalena Łuba¹
Piotr Wojskowicz¹
Jacek Dadan¹
Hanna Myśliwiec²
Katarzyna Choromańska³
Katarzyna Makarewicz⁴
Anna Zalewska⁵
Mateusz Maciejczyk⁶

¹Ist Department of General and Endocrine Surgery, Medical University of Białystok, Białystok, Poland; ²Department of Dermatology and Venereology, Medical University of Białystok, Białystok, Poland; ³Department of Oral Surgery, Medical University of Gdańsk, Gdańsk, Poland; ⁴Regional Centre for Transfusion Medicine in Białystok, Białystok, Poland; ⁵Experimental Dentistry Laboratory, Medical University of Białystok, Białystok, Poland; ⁶Department of Hygiene, Epidemiology and Ergonomics, Medical University of Białystok, Białystok, Poland

Background: Adrenal masses are the most common of all human tumors. The role of nitrosative stress and inflammation in cancer development has already been demonstrated. However, it is not known whether they are involved in the pathogenesis of adrenal tumors. The aim of the study was to investigate a cross-talk between nitrosative stress, inflammation and hypoxia-inducible factor (HIF-1 α) in 75 patients with different types of adrenal masses (non-functional incidentaloma, pheochromocytoma and Cushing's/Conn's adenoma).

Methods: The plasma concentrations of total nitric oxide (NO), S-nitrosothiols, peroxynitrite nitrotyrosine and the activity of serum myeloperoxidase (MPO) were measured spectrophotometrically, whereas concentrations of interleukin 1 beta (IL-1 β), tumor necrosis factor α (TNF- α) and hypoxia-inducible factor 1 alpha (HIF-1 α) were measured using commercial ELISA kits. The control group consisted of 50 healthy people matched by age and sex to the study group. The number of subjects was determined a priori based on our previous experiment (power of the test = 0.9; α = 0.05).

Results: We found significantly higher nitrosative stress ($\uparrow$ nitric oxide, $\uparrow$ peroxynitrite, $\uparrow$ S-nitrosothiols and $\uparrow$ nitrotyrosine) in the plasma of patients with adrenal tumors, which was accompanied by increased inflammatory ($\uparrow$ myeloperoxidase, $\uparrow$ interleukin 1 beta and $\uparrow$ tumor necrosis factor α) and hypoxia (HIF-1 α) biomarkers. Peroxynitrite and nitrotyrosine were positively correlated with aldosterone level. Nitrosative stress was also associated with inflammation and HIF-1 α . Interestingly, plasma nitrotyrosine and serum MPO differentiated patients with adrenal tumor from healthy individuals with high sensitivity and specificity. Moreover, using multivariate regression analysis, we showed that ONOO⁻ and IL-1 β depended on cortisol level, while ONOO⁻, nitrotyrosine and HIF-1 α were associated with aldosterone. Unfortunately, none of the assessed biomarkers differentiated between tumor types studied, suggesting that the severity of nitrosative damage and inflammation are similar in patients with incidentaloma, pheochromocytoma, and Cushing's or Conn's adenoma.

Conclusion: Adrenal tumors are associated with increased protein nitration/S-nitrosylation and inflammation.

Keywords: adrenal tumors, nitrosative stress, nitric oxide, peroxynitrite, S-nitrosothiols, nitrotyrosine, myeloperoxidase, interleukin 1 beta, tumor necrosis factor, α hypoxia-inducible factor

Introduction

Adrenal masses are usually benign neoplastic lesions detected accidentally during the diagnosis of other diseases.¹ They are the most common of all human tumors, and the frequency of their detection continues to increase, especially with age.^{2,3} Although

Correspondence: Mateusz Maciejczyk
Email mat.maciejczyk@gmail.com

most of adrenal masses are hormonally inactive, some of them may contribute to the overproduction of cortisol, aldosterone or catecholamines.^{4,5} Even though, adrenocortical carcinomas are very rare, the risk of adrenal masses becoming malignant increases with tumor size. It is estimated that 25% of adrenal tumors larger than 6 cm may become malignant.⁶ An adrenal masses is associated not only with the risk of malignancy, but also with the development of metabolic disturbances.^{7–9} In patients with pheochromocytoma, excessive secretion of catecholamines (dopamine, adrenaline and noradrenaline) may lead to the development of obesity and disorders of lipid and glucose metabolism, insulin resistance, diabetes and hypertension.⁷ Cushing's syndrome also leads to weight gain and, consequently, to the development of obesity and its metabolic complications, while Conn's syndrome is the cause of treatment-resistant hypertension.^{10,11} Nevertheless, due to the variety of adrenal tumors, their clinical symptoms are not specific and their diagnosis is difficult. The pathogenesis of adrenal masses is still not fully understood. Probably genetic factors have the greatest impact on the development of adrenal tumors.^{12,13} Indeed, the mutation of VHL/HIF axis is the risk factor of pheochromocytoma development.¹⁴ Hypoxia-induced factor (HIF-1) has various effects on tumor growth and metabolism, as well as metastasis, especially in cancer secreting catecholamines.¹⁵

Recent studies emphasize the crucial role of oxidative stress (OS) in the development of cancer.^{16–18} The production of reactive oxygen (ROS) and nitrogen (RNS) species is an inherent process of the oxygen metabolism of cells associated with many physiological and pathological processes in the human body.¹⁹ OS is closely associated to nitrosative stress.²⁰ Nitric oxide (NO) reacts with molecular oxygen, superoxide anion and metal cations, causing the formation of further reactive oxygen species.^{21,22} The excessive formation of ROS and RNS leads to oxidative and nitrosative damage to lipids, proteins and DNA.^{19,23} Proteins are particularly sensitive to the action of ROS and RNS because oxidation or nitrosylation of amino acid residues can lead to their denaturation, fragmentation and aggregation, resulting in impairment of their (proteins') function or even cell apoptosis.^{24,25} Peroxynitrite (ONOO[−]) is one of the most cytotoxic reactive forms of nitrogen and the factor with the greatest potential for protein oxidation. It is formed in the reaction of NO with O₂[−].^{26,27} Interestingly, its formation is promoted by an increase in inducible NOS isoform (iNOS) activity.²⁷ ONOO[−] in reaction with amino acids leads to irreversible modifications of

proteins, which results in the formation of carbonyl groups, as well as nitration, nitrosylation and dimerization of proteins.^{28–30} Moreover, both the formation of modified proteins and an increase in NO concentration can lead to the disruption of many signaling pathways and the initiation of inflammatory processes.^{21,22,31} Indeed, ONOO[−] and protein nitration products activate the nuclear factor kappa B (NF-κB), which induces the secretion of interleukin 1 (IL-1), interleukin 6 (IL-6), interleukin 8 (IL-8) and tumor necrosis factor α (TNF-α), intercellular adhesion molecule 1 (ICAM-1), as well as nitric oxide synthase (NOS).^{32,33} This leads to self-driving further oxidative/nitrosative damage.³⁴ NO is also the mediator of inflammation due to its enhancing effect of cyclooxygenases action.²⁰ Up to 20% of tumors are thought to be caused by inflammation. Cytokines produced in excess contribute to the transformation of healthy cells into neoplastic ones.³⁵

In our previous study, we found impaired enzymatic and non-enzymatic antioxidant barrier as well as increased oxidative damage to lipids, proteins, and DNA/RNA in plasma, serum and urine in patients with adrenal tumor.³⁶ This indicates a lack of effective protection against oxidative stress in patients with adrenal masses. So far, nothing is known about the role of nitrosative stress and inflammation in the development of adrenal tumors. Moreover, the diagnosis of adrenal tumors is often difficult, therefore the aim of this study was also to search their new diagnostic biomarkers.

Materials and Methods

The study was designed and conducted according to the Guidelines for Good Clinical Practice and the Declaration of Helsinki, as well as approved by the Bioethics Committee of the Medical University of Białystok (permission code: R-I-002/66/2015, APK.002.341.2020). All participants of this study gave their informed consent.

75 patients (39 women and 38 men aged from 49 to 65 years) with adrenal masses diameter > 1 cm and < 8 cm were qualified for this study. Patients had been diagnosed at internal medicine departments with an endocrinology profile and underwent elective endoscopic adrenalectomy at the 1st Department of General and Endocrine Surgery at the University Hospital in Białystok, Poland. Depending on the diagnosis, patients were divided into 3 groups: patients with non-functional incidentaloma (n = 25), pheochromocytoma (n = 25) and Cushing's/Conn's adenoma (n = 25). In the adenoma subgroup, 14 patients suffered from Cushing's syndrome and 11 from Conn's syndrome. Patients diagnosed with Conn's syndrome were taking potassium or spironolactone

(aldosterone receptor blocker) in the preoperative period. Patients with pheochromocytoma were treated with doxazosin (a selective alpha-1-adrenergic receptor blocker) for 10 to 14 days prior to surgery to avoid intraoperative hypertensive crisis. 26 patients had hypertension, that was diagnosed according to World Health Organizations guidelines. Hypertension was diagnosed if measuring on two different days the value of systolic (SBP) and/or diastolic (DBP) blood pressure was 140/90 (mmHg) or above. Blood pressure was measured on the non-dominant upper arm using Diagnosis UA-651 A&D Medical apparatus. The cuff was put on tightly to the exposed arm, about 2–3 cm above the elbow flexion. Two measurements at intervals of several minutes were taken.

The control group consisted of 50 healthy people (25 women and 25 men aged 50 to 65) who underwent a dental follow-up examination at the Specialist Dental Clinic at the Medical University of Białystok. None of the volunteers had periodontal disease (probing pocket depth (PPD) ≤ 2 ; bleeding on probing (BOP) < 15) or active caries (decayed teeth < 1). Their full blood counts and biochemical blood parameters (INR, K^+ , Na^+ , creatinine ALT and AST) were within the reference values.

Participants for both the control and study groups were uniformly classified on the basis of a negative history of the following diseases: cardiovascular diseases (other than hypertension), neoplastic diseases, autoimmune diseases (Hashimoto's disease, ulcerative colitis and Crohn's disease), diseases of the respiratory, genitourinary and digestive systems, metabolic diseases (insulin resistance, type 1 diabetes, mucopolysaccharidosis, osteoporosis and gout), infectious diseases (HIV/AIDS, hepatitis A, B or C), acute inflammation, abusing alcohol and smoking as well as pregnancy in women. All participants of the study denied taking antibiotics, glucocorticosteroids, nonsteroidal anti-inflammatory drugs and antioxidant supplements (including iron preparations) for three months prior to collecting material for the study. The clinical and laboratory characteristics of the control and study groups are shown in Table 1.

Blood and Urine Collection

The participants of the study declared, that they did not perform intense physical activity twenty-four hours before blood sampling. All blood samples from patients of control and study groups were collected in a fasting state into serum and EDTA tubes (SARSTEDT, S-Monovette) and centrifuged for 10 minutes at 4°C and 4000 rpm. The urine samples were collected from the first-morning portion of urine from the middle stream immediately after bedtime into a sterile

Table 1 Clinical and Laboratory Characteristics of the Controls, Incidentaloma, Pheochromocytoma, and Cushing's/Conn's Adenoma Patients. Results are Presented as Median with 25% and 75% Percentiles

	Controls (n=50)	Incidentaloma (n=25)	Pheochromocytoma (n=25)	Cushing's/Conn's Adenoma (n=25)	ANOVA
Age	60 (53–65)	61 (54–65)	60 (51–64)	59 (52–65)	p=0.8913
BMI (kg/m^2)	23.1 (22.6–23.7)	29.3*** (26.4–30.1)	26.7*** (24.7–29.1)	29.9*** (29.1–30.2)	p<0.0001
Glucose (mg/dL)	76 (72–80)	101**** (86.5–107)	84* (78–93)	98*** (86–110)	p<0.0001
Serum cortisol before 10 a.m. ($\mu g/dL$)	12.25 (9.05–17)	12.3 (8.25–18.9)	12.5 (10.35–18.95)	16.7 (11.65–18.55)	p=0.1369
Aldosterone (ng/dL)	12.3 (7.6–21.2)	11.8** (6.7–21.5)	15.2 (11.1–21.3)	19.03** (14.3–36.9)	p=0.0025
Urine metanephrine ($\mu g/24h$)	100 (87–177)	97**** (76–177)	401**** (321–518)	122**** (89–202)	p<0.0001
Urine normetanephrine ($\mu g/24h$)	207.2 (144.5–319.3)	235**** (186–340)	567**** (421–772.5)	391*** (277–439)	p<0.0001
K^+ (mmol/L)	4.4 (4.1–4.7)	4.5 (4.3–4.8)	4.6 (4.3–4.8)	4.3 (3.9–4.6)	p=0.0688
Na^+ (mmol/L)	139 (138–141)	141 (139–141)	139 (137–141)	139 (137–141)	p=0.1078
CRP (mg/L)	5.5 (5.27–5.65)	5.6* (2.35–8.1)	8.35* (5.72–10.1)	5.8 (2.31–9.81)	p=0.0151
WBC ($10^3/\mu L$)	7.55 (6.57–8.3)	7.08 (4.97–9.01)	7.08 (6.35–8.41)	7.18 (6.67–8.81)	p=0.9292
RBC ($10^6/\mu L$)	4.6 (4.47–4.87)	4.79* (4.49–5.06)	4.4 (4.15–4.6)	4.66 (4.36–4.8)	p=0.0206
HGB (g/dL)	13.8 (13.3–14.1)	14.3* (13.5–14.8)	13.2 (12.5–14.2)	14.1 (13.5–14.6)	p=0.013
PLT ($10^3/\mu L$)	295 (277–300)	237** (200–289)	283*** (227–316)	197**** (158–253)	p<0.0001

Notes: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 indicate significant differences from the controls; ^ p<0.05, ****p<0.0001 indicate significant differences from the pheochromocytoma group; ~p<0.05, ~~~p<0.01, ~~~~p<0.001 indicate significant differences from the Cushing's/Conn's group.

Abbreviations: BMI, body mass index; CRP, C reactive protein; HGB, hemoglobin; PLT, platelet count; RBC, red blood cell count; WBC, white blood cell count; UA, uric acid.

disposable container and centrifuged for 5 minutes at 1500 rpm. In order to protect against oxidation, butylated hydroxytoluene (BHT) was added to the supernatant (10 μ L of 0.5 M BHT/1 mL of plasma/serum and urine and stored at -80°C until final examinations were made.^{16,37}

Laboratory Measurements

Full blood count, as well as serum biochemical test (cortisol before 10 a.m., serum aldosterone, glucose Na^+ , K^+ , and urine metanephrine and normetanephrine) were determined using automated blood analyzers (Sysmex XN1000, Abbott Diagnostics, Wiesbaden, Germany). In both groups, the laboratory tests were performed in the Laboratory of Biochemical Diagnostics, University Hospital in Białystok, Poland.

Nitrosative Stress

All reagents to this study were purchased from Sigma-Aldrich (Nümbrecht, Germany and/or Saint Louis, MO, USA). All determinations were conducted in duplicate samples and results were standardized to 1 mg of total protein. NO concentration was determined in triplicates. The total protein content was analyzed spectrophotometrically using the bicinchoninic acid (BCA) method. Commercial diagnostic kit (Thermo Scientific PIERCE BCA Protein Assay; Rockford, IL, USA) was performed according to manufacturer's instructions. The absorbance and fluorescence were measured using BioTek Synergy H1 (Winooski, VT, USA) Microplate Reader.

The plasma concentration of total nitric oxide (NO) was measured spectrophotometrically method, using sulfanilamide and NEDA-2 HCl (N-(1-naphthyl)-ethylenediamine dihydrochloride).^{38,39} The plasma concentration of S-nitrosothiols was evaluated spectrophotometrically in the reaction of the Griess reagent with Cu^{2+} ions.⁴⁰ The concentration of plasma peroxynitrite was estimated spectrophotometrically according to the reaction of peroxynitrite-mediated nitration resulting in the formation of nitrophenol.⁴¹ The absorbance of NO and S-nitrosothiols was measured at 490 nm, whereas peroxynitrite at 320 nm. The concentration of plasma nitrotyrosine was analyzed spectrophotometrically using ELISA method. Commercial diagnostic kit (Immundiagnostik AG; Bensheim, Germany) was conducted in accordance with manufacturer's instructions.

The activity of serum myeloperoxidase (MPO) was measured spectrophotometrically at 450 nm. The sulfanilamide hexadecyl trimethyl ammonium, ortho-dianisidine dihydrochloride, and hydrogen peroxide were used as

reagents.⁴² The concentrations of interleukin 1 beta (IL-1 β), tumor necrosis factor α (TNF- α) and hypoxia-inducible factor 1 alpha (HIF-1 α) were measured using commercial ELISA kits from EIAab, Wuhan, China. We followed the instructions provided by the manufacturer.

Statistical Analysis

Statistical analysis was performed using the GraphPad Prism 8.4.3 for MacOS (GraphPad Software, Inc. La Jolla, USA) according to Shapiro–Wilk test, Levene's test, Kruskal–Wallis ANOVA test and post-hoc Dunn's test. Statistical significance was established at $p \leq 0.05$ and multiplicity-adjusted p-values were calculated for all comparisons. Data was expressed as median with 25% and 75% percentiles. Relations between various parameters were tested by Spearman correlation coefficient. Multivariate analysis of the simultaneous impacts of many independent variables on one quantitative dependent variable was conducted by means of linear regression. Cortisol, metanephrine, normetanephrine and aldosterone were included as independent variables. A 95% CI was reported along with regression parameters. Based on receiver operating characteristic (ROC) curves, the diagnostic value of the analyzed biomarkers, ie, sensitivity and specificity of the test, was evaluated. The number of subjects was determined based on our previous experiment, assuming that the power of the test = 0.9 and $\alpha = 0.05$. ClinCalc online calculator was used to estimate the sample size.

Results

Table 1 shows a comparison of the clinical and laboratory characteristics of the controls and patients with adrenal masses. BMI of patients with adrenal masses was higher than the controls. Serum glucose concentration was increased in incidentaloma and Cushing's/Conn's adenoma patients compared to the healthy controls. In Cushing's/Conn's adenoma patients the serum concentration aldosterone was greater than the controls. Additionally, aldosterone level was higher in Cushing's/Conn's adenoma in comparison with incidentaloma patients. Urinary concentrations of metanephrine and normetanephrine were higher in pheochromocytoma group as compared to other groups. The CRP level was greater pheochromocytoma than the controls and incidentaloma patients. We found content of PLT in patients with incidentaloma and Cushing's/Conn's adenoma as compared to the controls. Moreover, patients with Cushing's/Conn's adenoma have greater amount of PLT than pheochromocytoma one.

Total Plasma Nitric Oxide (NO)

NO total plasma concentration of Cushing's Conn's adenoma was increased (+131%, $p=0.0018$) as compared to the controls. Additionally, we found significantly lower plasma concentration of total NO in incidentaloma (-71% , $p=0.0015$) and pheochromocytoma (-55% , $p=0.0174$) than Cushing's Conn's adenoma patients (Figure 1A).

Plasma Peroxynitrite (ONOO⁻)

Plasma concentration of ONOO⁻ was increased only in Cushing's Conn's adenoma (+62%, $p<0.0001$) patients as compared to the controls. Moreover, the ONOO⁻ plasma concentration in Cushing's Conn's adenoma subgroup was higher than incidentaloma (+75%, $p=0.0002$) and pheochromocytoma (+47%, $p=0.0097$) subgroups. We also observed elevated peroxynitrite concentrations in OB

Figure 1 Violin plots of plasma total NO (A), ONOO⁻ (B), S-nitrosothiols (C) and nitrotyrosine (D) of the control, incidentaloma, pheochromocytoma and Cushing's Conn's adenoma patients. Results are presented as median with 25% and 75% percentiles. ** $p<0.01$, *** $p<0.001$, **** $p<0.0001$ indicate significant differences from the controls; ~ $p<0.05$, ~~ $p<0.01$, ~~~ $p<0.001$ indicate significant differences from the Cushing's Conn's adenoma group; total nitric oxide (NO), peroxynitrite (ONOO⁻).

+HYP (+44%, $p=0.0011$) and OB+MS (+60%, $p=0.0009$) patients compared to OB ones (Figure 1B).

Plasma S-Nitrosothiols

We noticed greater plasma concentration of S-nitrosothiols in each group of adrenal masses patients: incidentaloma (+37%, $p<0.0001$), pheochromocytoma (+42%, $p<0.0001$) and Cushing's Conn's adenoma (+44%, $p<0.0001$) than the controls (Figure 1C).

Plasma Nitrotyrosine

Plasma nitrotyrosine concentration was greater in incidentaloma (+64%, $p=0.0008$), pheochromocytoma (+88%, $p<0.0001$) and Cushing's Conn's adenoma (+154%, $p<0.0001$) patients than the controls. Further on, we noticed that Cushing's Conn's adenoma (+55%, $p=0.0218$) patients had increased plasma concentration of nitrotyrosine than incidentaloma patients (Figure 1D).

Serum Myeloperoxidase (MPO)

We observed higher plasma concentration of MPO in each group of adrenal masses patients: incidentaloma (+39%, $p<0.0001$), pheochromocytoma (+41%, $p<0.0001$) and Cushing's Conn's adenoma (+42%, $p<0.0001$) in comparison with the controls (Figure 2A).

Interleukin I Beta (IL-1 β)

We observed that plasma concentration of IL-1 β was significantly increased in patients with adrenal masses: incidentaloma (+33%, $p=0.0002$), pheochromocytoma (+16%, $p=0.0099$) and Cushing's Conn's adenoma (+42%, $p<0.0001$) patients in comparison with the controls (Figure 2B).

Tumor Necrosis Factor α (TNF- α)

Plasma concentration of TNF- α was greater in each group of adrenal masses patients: incidentaloma (+39%, $p<0.0001$), pheochromocytoma (+22%, $p=0.004$) and Cushing's Conn's adenoma (+33%, $p<0.0001$) than the controls (Figure 2C).

Hypoxia-Inducible Factor I Alpha (HIF-1 α)

Plasma HIF-1 α concentration was markedly higher in incidentaloma (+12%, $p=0.0002$), pheochromocytoma (+13%, $p<0.0001$) and Cushing's Conn's adenoma (+18%, $p<0.0001$) patients than the controls (Figure 2D).

Correlations

We found positive correlations between ONOO $^-$ and aldosterone ($R=0.337$, $p=0.004$), as well nitrotyrosine and aldosterone ($R=0.41$, $p<0.0001$). NO total plasma concentration was associated positively with plasma ONOO $^-$ ($R=0.717$, $p<0.0001$), nitrotyrosine ($R=0.434$, $p<0.0001$) and S-nitrosothiols ($R=0.313$, $p=0.006$). Plasma ONOO $^-$ correlated positively with nitrotyrosine ($R=0.711$, $p<0.0001$) and S-nitrosothiols ($R=0.314$, $p=0.006$). Plasma nitrotyrosine was positively associated with S-nitrosothiols ($R=0.23$, $p=0.047$).

Nitrosative stress was also associated with inflammation. We observed positive correlations ONOO $^-$ with MPO ($R=0.591$, $p<0.0001$), IL-1 β ($R=0.356$, $p=0.002$) and TNF- α ($R=0.337$, $p=0.003$), as well as nitrotyrosine with MPO ($R=0.338$, $p=0.003$), IL-1 β ($R=0.598$, $p<0.0001$) and TNF- α ($R=0.611$, $p<0.0001$). The positive correlations were also seen between total NO and MPO ($R=0.441$, $p<0.0001$), and S-nitrosothiols and MPO ($R=0.307$, $p=0.007$).

Interestingly, we also found correlations between hypoxia and nitrosative stress, inflammation and clinical parameters. The positive correlations were observed between HIF-1 α and ONOO $^-$ ($R=0.389$, $p=0.001$), nitrotyrosine ($R=0.636$, $p<0.0001$), IL-1 β ($R=0.418$, $p<0.0001$), TNF- α ($R=0.514$, $p<0.0001$) and aldosterone ($R=0.274$, $p=0.019$).

BMI was positively associated with serum concentration of glucose ($R=0.253$, $p=0.033$) and negatively with urine metanephrine ($R=-0.339$, $p=0.003$). Serum concentration of glucose correlated negatively with urine metanephrine ($R=-0.346$, $p=0.003$) and normetanephrine ($R=-0.246$, $p=0.0039$). We also observed positive correlations between aldosterone and urinary normetanephrine ($R=0.261$, $p=0.026$), metanephrine and normetanephrine ($R=0.246$, $p<0.0001$) and IL-1 β and TNF- α ($R=0.78$, $p<0.0001$).

Correlations between nitrosative stress biomarkers and inflammation and clinical parameters are shown in Figure 3.

Multivariate Regression Analysis

Using multivariate regression analysis, we showed that concentration of ONOO $^-$ and IL-1 β depend on cortisol level, while ONOO $^-$, nitrotyrosine and HIF-1 α varies with aldosterone. Results of multifactorial regression analysis are shown in Table 2.

ROC Analysis

We also analyzed diagnostic usefulness of the estimated nitrosative stress and inflammatory biomarkers. The

Figure 2 Violin plots of serum MPO (A), plasma IL-1 β (B), TNF- α (C) and HIF-1 α (D) of the control, incidentaloma, pheochromocytoma and Cushing's Conn's adenoma patients. Results are presented as median with 25% and 75% percentiles. ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ indicate significant differences from the controls; myeloperoxidase (MPO), interleukin 1 beta (IL-1 β) and tumor necrosis factor α (TNF- α).

results of ROC analysis are presented in Table 3. Interestingly, plasma nitrotyrosine and MPO with high sensitivity and specificity differentiates adrenal tumor patients from the healthy individuals (Table 3).

Discussions

The etiology of adrenal tumors is not well understood. Recent studies indicate that some patients are characterized

by chromosomal abnormalities, deficiencies in growth factor production as well as diminished antioxidant barrier and higher oxidative stress level.^{36,43} However, the role of NO metabolites and their association with inflammatory molecules is still unknown in patients with adrenal tumors. This study is the first to demonstrate systemic nitrosative stress and inflammation in different types of adrenal masses. Additionally, we have shown that plasma nitrotyrosine

Figure 3 Correlation heat map between the analyzed nitrosative stress, inflammation and clinical parameters in serum and plasma of the patients with adrenal masses; body mass index (BMI), C reactive protein (CRP), nitric oxide (NO), myeloperoxidase (MPO), interleukin 1 beta (IL-1β), tumor necrosis factor α (TNF-α) and hypoxia-inducible factor 1 alpha (HIF-1α).

may be a potential biomarker differentiating healthy individuals from cases with incidentaloma, pheochromocytoma, and Cushing's/Conn's adenoma.

NO is an important signaling molecule involved in the regulation of many physiological processes. This compound also has a second face because, in a high concentration, NO exhibits strong cytotoxic properties.^{19,27,44} The biological activity of NO is mainly manifested by protein S-nitrosylation and tyrosine nitration.⁴⁵ Therefore, in adrenal tumor patients, we observed not only increased NO formation, but also higher S-nitrosothiols and nitrotyrosine levels. NO may be a promoter of carcinogenic nitrosamines, while nitrosylation of primary arylamines is directly responsible for its mutagenic effects.⁴⁶ It is believed that nitrosative damage to DNA and disruption of replication and transcription processes represent an early stage of tumor development.⁴⁷ Nevertheless, NO may also contribute to tumorigenesis by suppressing the immune response and inducing angiogenesis.⁴⁸ Indeed, cytokine-activated macrophages produce large amounts of NO, which increase, on a positive feedback, the formation of cytokines, chemokines, and growth factors.⁴⁹ This may be confirmed by the positive correlation between NO and MPO in the adrenal tumor patients. Furthermore, nitric oxide reacting with superoxide radical generates peroxynitrite, which is the most potent oxidizing and nitrating agents.^{27,50} In our study, this may be confirmed by the

positive correlation of ONOO⁻ with nitrotyrosine and S-nitrosothiols. Although S-nitrosylation has important biological functions, the increased formation of S-nitrosothiols disrupts many enzymatic and structural proteins by forming protein disulfides and attaching nitroxyl moieties.^{51–53} Protein modified by nitrosative stress tend to form aggregates, which accumulate in tissues and reduce their susceptibility to proteolytic degradation. These complexes can also stimulate the NADPH oxidase (NOX) activity, which is the primary source of free radicals in the cell.⁵⁴ NOX activation also increases the synthesis and release of inflammatory mediators,⁵⁵ which may be supported by the positive relationship between S-nitrosothiols and MPO. However, NO-mediated mitochondrial dysfunction also has an important role in tumor induction and progression. NO has been shown to down-regulation of glyceraldehyde-3-phosphate dehydrogenase activity (through S-nitrosylation and subsequent ADP-ribosylation), leading to inhibition of glycolysis and a decrease in ATP cellular level.^{56–59} ONOO⁻ can also suppress ATP synthesis by inhibiting mitochondrial aconitase in the citric acid cycle. Thus, the cytotoxic effects of NO are associated with inhibition of key cellular enzymes.⁶⁰ ONOO⁻ may also exacerbate inflammation,^{32,61} as evidenced by a positive correlation with MPO, IL-1β and TNF-α.

We also found elevated concentration of HIF-1α in patients with adrenal tumors. HIF-1α is a crucial transcription factor in cancer progression.¹⁵ HIF-1α shows various effects depending on the oxygen supply. Under the physiological concentration of oxygen in cells, it is broken down by the ubiquitin-proteasome pathway (UPP).⁶² However, in hypoxic states, its accumulation is excessive, which leads to the dysregulation of many genes involved in the pathogenesis of cancer. It was shown that HIF-1 is activated under oxidative stress conditions.⁶³ Indeed, high concentration of ROS produced in the mitochondria leads to stabilization of HIF-1α.⁶⁴ Moreover, studies from recent years indicate that NO takes part in the stabilization of HIF-1α directly by S-nitrosylation and indirectly by inhibition of procollagen-proline dioxygenase (PHDs).^{65,66} Precise cellular responses and protein activation may depend on various concentrations and duration of exposure to NO.^{67,68} The HIF-1α response to NO exposure is immediate. NO can stabilize HIF-1α only in concentrations above the threshold amount leading to its excessive accumulation. On the other hand, lowering the NO

Table 2 Multifactorial Regression Analysis of Nitrosative Stress and Inflammatory Biomarkers in Adrenal Tumor Patients

Biomarker	$\beta 1$: Cortisol			$\beta 2$: Metanephrine			$\beta 3$: Normetanephrine			$\beta 4$: Aldosterone		
	Estimate	95% CI	P value	Estimate	95% CI	P value	Estimate	95% CI	P value	Estimate	95% CI	P value
Total NO	-0.9032	-1.950 to 0.1439	0.0897	-0.01666	-0.04279 to 0.009469	0.2076	0.002921	-0.03319 to 0.03903	0.8722	0.1679	-0.3978 to 0.7336	0.5556
Peroxyntirite	-0.7573	-1.481 to -0.03359	0.0405	-0.003478	-0.02154 to 0.01458	0.7019	-0.00785	-0.03281 to 0.01711	0.5323	0.5457	0.1547 to 0.9367	0.0069
S-nitrosothiols	-0.1579	-0.4363 to 0.1206	0.2619	-0.0001034	-0.007052 to 0.006846	0.9764	-0.00007228	-0.009675 to 0.009530	0.9881	-0.0276	-0.1780 to 0.1228	0.7155
Nitrotyrosine	-0.1827	-0.8154 to 0.4499	0.5663	0.0001806	-0.01561 to 0.01597	0.9819	-0.003021	-0.02484 to 0.01880	0.7831	0.3514	0.009547 to 0.6932	0.0441
MPO	-0.000006629	-0.0007959 to 0.0007827	0.9867	-0.000001015	-0.00002071 to 0.00001868	0.9184	0.000003794	-0.00002343 to 0.00003101	0.7817	0.0000716	-0.0003548 to 0.0004980	0.7386
IL-1 β	-0.04327	-0.08314 to -0.003399	0.0339	0.0001613	-0.0008315 to 0.001154	0.7467	-0.001012	-0.002385 to 0.0003614	0.146	0.01017	-0.01149 to 0.03184	0.352
TNF- α	-0.0101	-0.1585 to 0.1383	0.8924	0.0005452	-0.003159 to 0.004249	0.7699	-0.003281	-0.008400 to 0.001838	0.2053	0.02296	-0.05723 to 0.1032	0.5696
HIF-1 α	-1.521	-15.05 to 12.01	0.8232	0.09888	-0.2388 to 0.4366	0.5609	-0.3156	-0.7823 to 0.1510	0.1816	11.16	3.846 to 18.47	0.0033

Abbreviations: NO, nitric oxide; MPO, myeloperoxidase; IL-1 β , interleukin 1 beta; TNF- α , tumor necrosis factor α ; HIF-1 α , hypoxia-inducible factor 1 alpha.

Table 3 Area Under the Curve of Nitrosative Stress and Inflammatory Biomarkers Between Adrenal Tumor Patients and the Controls

Biomarker	Control Group	Study Group	P value	AUC	95% CI	Cut Off	Sensitivity%	95% CI	Specificity%	95% CI
NO	14.24 (12.06–15.93)	17.78 (7.907–42.07)	0.1538	0.5755	0.4705 to 0.6805	< 15.40	68	54.19% to 79.24%	54.67	43.45% to 65.43%
Peroxynitrite	25.35 (22.08–27.9)	29.32 (22.95–41.07)	0.0019	0.6643	0.5698 to 0.7587	< 26.56	58	44.23% to 70.62%	57.33	46.05% to 67.90%
S-nitrosothiols	18.47 (14.11–21.87)	25.48 (21.65–29.77)	<0.0001	0.8379	0.7662 to 0.9095	< 21.19	72	58.33% to 82.53%	82.67	72.57% to 89.58%
Nitrotyrosine	12.43 (9.802–15.12)	24.44 (17.41–34.66)	<0.0001	0.8867	0.8293 to 0.9440	< 15.18	76	62.59% to 85.70%	82.67	72.57% to 89.58%
MPO	0.1608 (0.1535–0.1664)	0.2268 (0.2121–0.2365)	<0.0001	0.9909	0.9731 to 1.000	< 0.1862	100	92.87% to 100.0%	98.67	92.83% to 99.93%
IL-1β	2.109 (1.717–2.373)	2.733 (2.25–3.37)	<0.0001	0.7935	0.7163 to 0.8707	< 2.358	74	60.45% to 84.13%	71.62	60.48% to 80.63%
TNF-α	11.79 (10.62–13.63)	15.48 (13.25–17.62)	<0.0001	0.8387	0.7717 to 0.9057	< 13.35	72	58.33% to 82.53%	73.33	62.37% to 82.02%
HIF-1α	710.7 (650.1–775.1)	801.8 (772.3–1004)	<0.0001	0.8229	0.7448 to 0.9011	< 773.6	74	60.45% to 84.13%	72	60.96% to 80.90%

Note: Results are presented as median with 25% and 75% percentiles.

Abbreviations: NO, nitric oxide; MPO, myeloperoxidase; IL-1β, interleukin 1 beta; TNF-α, tumor necrosis factor α; HIF-1α, hypoxia-inducible factor 1 alpha.

concentration below the minimum level leads to a decrease in the level and disappearance of HIF-1α.^{68–70} The above statement may explain the positive correlations of HIF-1α with ONOO[−] and nitrotyrosine in patients with adrenal tumors observed in our study. Additionally, we observed that HIF-1α was positively associated with IL-1β and TNF-α. Under hypoxic conditions, the activity of HIF-1α is closely related to inflammation.⁷¹ It regulates the secretion of cytokines, the differentiation of monocytes into macrophages accompanied by the secretion of cytokines such as IL-1β, IL-6, IL-12, IL-23 and TNF-α.^{72–74} It is important to note that HIF-1α may be stabilized by inflammatory cytokines, especially TNF-α, inducing positive feedback, stimulating further differentiation of monocytes into macrophage.^{71,75} Moreover, nuclear factor kappa B (NF-κB) plays a key role in the stabilization of HIF-1α by TNF-α, which intensifies HIF-1α-mediated inflammation under hypoxic conditions.⁷¹

Metabolic abnormalities accompanying adrenal masses may be responsible for increased inflammation and nitrosative stress. Semi-quinone radicals (formed in the oxidation of dopamine, epinephrine, and norepinephrine) have been shown to cause glutathione oxidation, lipoperoxidation, and DNA oxidative damage.³⁶ This promotes the formation of inflammatory mediators and enhances NADPH oxidase activity, which is not only an important source of free radicals but also cytokines and chemokines.⁷⁶ Catabolism of catecholamines by MAO and COMT enzymes may also increase NO production and interleukin secretion.⁷⁷ In our study, we also observed a higher BMI in patients with adrenal tumors compared to healthy controls. Although excessive catecholamine secretion leads to weight loss, it may also be involved in the development of obesity and metabolic disorders.⁷ Several studies have shown that catecholamines inhibit adiponectin secretion, which is significantly reduced in patients with adrenal masses.^{78–80} In transgenic mice with a deletion of the collagen domain of adiponectin, a lower concentration of circulating adiponectin was observed, which led to an increase in lipoprotein lipase activity and lipid removal.⁸¹ However, it should be noted that patients in the study group were only overweight but not obese.

Similarly, increased cortisol output may also disrupt redox homeostasis and inflammation. On the one hand, cortisol blocks cyclooxygenases (COX-1 and COX-2) responsible for the formation of prostaglandins and proteolytic enzymes (elastase and collagenase), impoverishing the phagocytosis process and protecting lysosomes against

the release of degrading hydrolytic enzymes.⁸² However, this hormone also increases hepatocyte's sensitivity to adrenaline and glucagon as well as intensifies gluconeogenesis by stimulating phosphoenolpyruvate carboxykinase and glucose-6-phosphatase activities.^{83,84} Cortisol also enhances adipose tissue lipolysis with accompanying release of glycerol and free fatty acids into circulation.⁸⁵ Therefore, it may be responsible for hyperglycemia and hyperlipidemia in adrenal masses patients. In our study, although glucose level was generally within reference values it was also significantly higher compared to controls. The highest glucose values were observed in patients with incidentaloma and Cushing's/Conn's adenoma. Therefore, metabolic abnormalities caused by higher cortisol/catecholamine output may be associated with systemic inflammation and nitrosative stress.⁸⁶ However, this hypothesis requires further research and clinical observations.

An important part of the study was also to determine the diagnostic utility of nitrosative stress and inflammatory biomarkers. Diagnosis of adrenal tumors is based on imaging studies in conjunction with evaluation of blood/urine hormones such as cortisol, metanephrine, and normetanephrine. Therefore, biomarkers for early and non-invasive diagnosis of adrenal cancer are still being sought. Using ROC analysis, we demonstrated that circulating S-nitrosothiols, nitrotyrosine, and MPO differentiate controls from adrenal tumor patients with very high sensitivity (>72%) and specificity (>83%). Of particular note is nitrotyrosine, whose levels correlate not only with inflammatory markers (MPO, IL-1 β , TNF- α) but also with HIF-1 α and aldosterone. In a multivariate regression model, we showed that nitrotyrosine is a predictor of aldosterone levels, which also supports the diagnostic value of this biomarker. It should be noted that nitrotyrosine determination is simple and inexpensive and can be performed in a routine diagnostic laboratory. Unfortunately, none of the assessed biomarkers did not differentiate between tumor types, suggesting that the severity of nitrosative damage and inflammation are similar in patients with incidentaloma, pheochromocytoma, and Cushing's/Conn's adenoma.

Our study is the first to evaluate the association of adrenal masses with nitrosative/nitrative stress, inflammation and HIF-1 expression. Although NO metabolites and the inflammatory response may be involved in adrenal masses development, the exact mechanism is still unknown. Due to the lack of ethics committee approval, we could not conduct animal studies to make the

conclusions more convincing. Further studies evaluating the role of redox imbalance, inflammation, and apoptosis in adrenal masses progression are needed.

Conclusions

1. Adrenal tumors are associated with increased protein nitration/S-nitrosylation and inflammation.
2. There is a need for molecular studies to explain disturbances in redox homeostasis, nitrosative stress, and inflammation in patients with adrenal tumors.

Data Sharing Statement

The original contributions presented in the study are included in the article. Further inquiries can be directed to the corresponding author.

Ethics Statement

The studies involving human participants were reviewed and approved by the Bioethics Committee of the Medical University of Białystok (permission code: R-I-002/66/2015, APK.002.341.2020). Written informed consent to participate in this study was provided by the participants.

Funding

This work was granted by the Medical University of Białystok, Poland (grant number: SUB/1/DN/21/003/1140, SUB/1/DN/21/002/3330). Dr. Mateusz Maciejczyk was supported by the Foundation for Polish Science (FNP).

Disclosure

The authors declare no conflicts of interest.

References

1. Song JH, Mayo-Smith WW. Incidentally discovered adrenal mass. *Radiol Clin North Am*. 2011;49(2):361–368. doi:10.1016/j.rcl.2010.10.006
2. Nieman LK. Approach to the patient with an adrenal incidentaloma. *J Clin Endocrinol Metab*. 2010;95(9):4106–4113. doi:10.1210/jc.2010-0457
3. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. *Endocr Rev*. 2004;25(2):309–340. doi:10.1210/er.2002-0031
4. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). *Ann Intern Med*. 2003;138(5):424. doi:10.7326/0003-4819-138-5-200303040-00013
5. Jason DS, Oltmann SC. Evaluation of an adrenal incidentaloma. *Surg Clin North Am*. 2019;99(4):721–729. doi:10.1016/j.suc.2019.04.009
6. Bhooster IR, Hill H, Greenfield JG. The adrenogenital syndrome associated with cortical hyperplasia; the results of unilateral adrenalectomy. *Br J Surg*. 1932;19:557–570. doi:10.1002/bjs.1800197606

7. Erlic Z, Beuschlein F. Metabolic alterations in patients with pheochromocytoma. *Exp Clin Endocrinol Diabetes*. 2019;127(2–03):129–136. doi:10.1055/a-0649-0960
8. Tong C, England P, Champion de Crespigny P, Millar R, Conn J. Diabetes mellitus as the only manifestation of occult pheochromocytoma prior to acute haemorrhage in pregnancy. *Aust N Z J Obstet Gynaecol*. 2005. doi:10.1111/j.1479-828X.2005.00344.x
9. Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. *Endocrinol Metab*. 2017;32(2):200. doi:10.3803/EnM.2017.32.2.200
10. Yozamp N, Vaidya A. Assessment of mild autonomous cortisol secretion among incidentally discovered adrenal masses. *Best Pract Res Clin Endocrinol Metab*. 2021;35(1):101491. doi:10.1016/j.beem.2021.101491
11. Pieroni J, Yamazaki Y, Gao X, et al. Cellular senescence in human aldosterone-producing adrenocortical cells and related disorders. *Biomedicine*. 2021;9(5):567. doi:10.3390/biomedicine9050567
12. Taïeb D, Pacak K. Genetic determinants of pheochromocytoma and paraganglioma imaging phenotypes. *J Nucl Med*. 2020;61(5):643–645. doi:10.2967/jnumed.120.245613
13. Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. *Curr Probl Cancer*. 2014;38(1):7–41. doi:10.1016/j.crrprobcancer.2014.01.001
14. Fishbein L, Leshchiner I, Walter V, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. *Cancer Cell*. 2017;31(2):181–193. doi:10.1016/j.ccell.2017.01.001
15. Wigerup C, Pählman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. *Pharmacol Ther*. 2016;164:152–169. doi:10.1016/j.pharmthera.2016.04.009
16. Zińczuk J, Maciejczyk M, Zaręba K, et al. Antioxidant barrier, redox status, and oxidative damage to biomolecules in patients with colorectal cancer. can malondialdehyde and catalase be markers of colorectal cancer advancement? *Biomolecules*. 2019;9(10):637. doi:10.3390/biom9100637
17. Mena S, Ortega A, Estrela JM. Oxidative stress in environmental-induced carcinogenesis. *Mutat Res Genet Toxicol Environ Mutagen*. 2009;674(1–2):36–44. doi:10.1016/j.mrgentox.2008.09.017
18. Poprac P, Jomova K, Simunkova M, Kollar V, Rhodes CJ, Valko M. Targeting free radicals in oxidative stress-related human diseases. *Trends Pharmacol Sci*. 2017;38(7):592–607. doi:10.1016/j.tips.2017.04.005
19. Lushchak VI. Free radicals, reactive oxygen species, oxidative stress and its classification. *Chem Biol Interact*. 2014;224c:164–175. doi:10.1016/j.cbi.2014.10.016
20. Ługowski M, Sączko J, Julita Kulbacka TB. Reactive oxygen and nitrogen species. *Pol Merkuri Lek*. 2011;31(185):313–317.
21. Supruniuk E, Maciejczyk M, Zalewska A, Górski J, Chabowski A. Blood profile of cytokines, chemokines, growth factors, and redox biomarkers in response to different protocols of treadmill running in rats. *Int J Mol Sci*. 2020;21(21):8071. doi:10.3390/ijms21218071
22. Skutnik-Radziszewska A, Maciejczyk M, Flisiak I, et al. Enhanced inflammation and nitrosative stress in the saliva and plasma of patients with plaque psoriasis. *J Clin Med*. 2020;9(3):745. doi:10.3390/jcm9030745
23. Förstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. *Nat Clin Pract Cardiovasc Med*. 2008;5(6):338–349. doi:10.1038/ncpcardio1211
24. Subramaniam R, Fan XJ, Scivittaro V, et al. Cellular oxidant stress and advanced glycation endproducts of albumin: caveats of the dichlorofluorescein assay. *Arch Biochem Biophys*. 2002;400(1):15–25. doi:10.1006/abbi.2002.2776
25. Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. *Amino Acids*. 2003;25(3–4):207–218. doi:10.1007/s00726-003-0011-2
26. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. *Amino Acids*. 2003;25(3–4):295–311. doi:10.1007/s00726-003-0018-8
27. Lufano M, Balazy M. Interactions of peroxynitrite and other nitrating substances with human platelets: the role of glutathione and peroxynitrite permeability. *Biochem Pharmacol*. 2003;65(4):515–523. doi:10.1016/S0006-2952(02)01584-8
28. Ghezzi P, Bonetto V. Redox proteomics: identification of oxidatively modified proteins. *Proteomics*. 2003;3(7):1145–1153. doi:10.1002/pmic.200300435
29. Aulak KS, Miyagi M, Yan L, et al. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. *Proc Natl Acad Sci U S A*. 2001;98(21):12056–12061. doi:10.1073/pnas.221269198
30. Matough FA, Budin SB, Hamid ZA, Alwahaibi N, Mohamed J. The role of oxidative stress and antioxidants in diabetic complications. *Sultan Qaboos Univ Med J*. 2012;12(1):5–18. doi:10.12816/0003082
31. Maciejczyk M, Taranta-Janusz K, Wasilewska A, Kossakowska A, Zalewska A. A case-control study of salivary redox homeostasis in hypertensive children. can salivary uric acid be a marker of hypertension? *J Clin Med*. 2020;9(3):837. doi:10.3390/jcm9030837
32. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev*. 2007;87(1):315–424. doi:10.1152/physrev.00029.2006
33. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. *Eur Heart J*. 2012;33(7):829–837. doi:10.1093/eurheartj/ehs304
34. Maciejczyk M, Szulimowska J, Taranta-Janusz K, Wasilewska A, Zalewska A. Salivary gland dysfunction, protein glycooxidation and nitrosative stress in children with chronic kidney disease. *J Clin Med*. 2020;9(5):1285. doi:10.3390/jcm9051285
35. Karin M. NF-kappaB as a critical link between inflammation and cancer. *Cold Spring Harb Perspect Biol*. 2009;1(5):a000141–a000141. doi:10.1101/cshperspect.a000141
36. Choromańska B, Myśliwiec P, Kozłowski T, et al. Antioxidant barrier and oxidative damage to proteins, lipids, and DNA/RNA in adrenal tumor patients. *Oxid Med Cell Longev*. 2021;2021:5543531. doi:10.1155/2021/5543531
37. Choromańska B, Myśliwiec P, Łuba M, et al. The impact of hypertension and metabolic syndrome on nitrosative stress and glutathione metabolism in patients with morbid obesity. *Oxid Med Cell Longev*. 2020;2020:1–10. doi:10.1155/2020/1057570
38. Grisham MB, Johnson GG, Lancaster JR. Quantitation of nitrate and nitrite in extracellular fluids. *Methods Enzymol*. 1996;268:237–246. doi:10.1016/s0076-6879(96)68026-4
39. Borys J, Maciejczyk M, Antonowicz B, et al. Glutathione metabolism, mitochondria activity, and nitrosative stress in patients treated for mandible fractures. *J Clin Med*. 2019;8(1):127. doi:10.3390/jcm8010127
40. Wink DA, Kim S, Coffin D, et al. Detection of S-nitrosothiols by fluorometric and colorimetric methods. *Methods Enzymol*. 1999;301:201–211. doi:10.1016/S0076-6879(99)01083-6
41. Beckman JS, Ischiropoulos H, Zhu L, et al. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. *Arch Biochem Biophys*. 1992;298(2):438–445. doi:10.1016/0003-9861(92)90432-V
42. Kruidenier L, Kuiper I, van Duijn W, et al. Imbalanced secondary mucosal antioxidant response in inflammatory bowel disease. *J Pathol*. 2003;201(1):17–27. doi:10.1002/path.1408
43. Vaidya A, Flores SK, Cheng Z-M, et al. EPAS1 mutations and paragangliomas in cyanotic congenital heart disease. *N Engl J Med*. 2018;378(13):1259–1261. doi:10.1056/nejmc1716652
44. Förstermann U. Nitric oxide and oxidative stress in vascular disease. *Pflugers Arch Eur J Physiol*. 2010;459(6):923–939. doi:10.1007/s00424-010-0808-2

45. Wiseman DA, Thurmond DC. The good and bad effects of cysteine S-nitrosylation and tyrosine nitration upon insulin exocytosis: a balancing act. *Curr Diabetes Rev.* 2012;8(4):303–315. doi:10.2174/157339912800840514
46. Montenegro MF, Sundqvist ML, Nihlén C, et al. Profound differences between humans and rodents in the ability to concentrate salivary nitrate: implications for translational research. *Redox Biol.* 2016;10:206–210. doi:10.1016/j.redox.2016.10.011
47. Khan FH, Dervan E, Bhattacharyya DD, McAuliffe JD, Miranda KM, Glynn SA. The role of nitric oxide in cancer: master regulator or not? *Int J Mol Sci.* 2020;21(24):9393. doi:10.3390/ijms21249393
48. Zou D, Li Z, Lv F, et al. Pan-cancer analysis of NOS3 identifies its expression and clinical relevance in gastric cancer. *Front Oncol.* 2021;11:592761. doi:10.3389/fonc.2021.592761
49. Palmieri EM, McGinity C, Wink DA, McVicar DW. Nitric oxide in macrophage immunometabolism: hiding in plain sight. *Metabolites.* 2020;10(11):429. doi:10.3390/metabo10110429
50. Toczewska J, Konopka T, Zalewska A, Maciejczyk M. Nitrosative stress biomarkers in the non-stimulated and stimulated saliva, as well as gingival crevicular fluid of patients with periodontitis: review and clinical study. *Antioxidants.* 2020;9(3). doi:10.3390/antiox9030259
51. Fernando V, Zheng X, Walia Y, Sharma V, Letson J, Furuta S. S-nitrosylation: an emerging paradigm of redox signaling. *Antioxidants (Basel, Switzerland).* 2019;8(9):404. doi:10.3390/antiox8090404
52. Jour'd'Heuil D, Hallén K, Feelisch M, Grisham MB. Dynamic state of S-nitrosothiols in human plasma and whole blood. *Free Radic Biol Med.* 2000;28(3):409–417. doi:10.1016/S0891-5849(99)00257-9
53. Drygalski K, Siewko K, Chomentowski A, et al. Phloroglucinol strengthens the antioxidant barrier and reduces oxidative/nitrosative stress in Nonalcoholic Fatty Liver Disease (NAFLD). *Oxid Med Cell Longev.* 2021;2021:1–18. doi:10.1155/2021/8872702
54. Żebrowska E, Chabowski A, Zalewska A, Maciejczyk M. High-sugar diet disrupts hypothalamic but not cerebral cortex redox homeostasis. *Nutrients.* 2020;12(10):3181. doi:10.3390/nu12103181
55. Maciejczyk M, Gerreth P, Zalewska A, Hojan K, Gerreth K. Salivary gland dysfunction in stroke patients is associated with increased protein glycoxidation and nitrosative stress. *Oxid Med Cell Longev.* 2020;2020:6619439. doi:10.1155/2020/6619439
56. Szabó C, Módis K. Pathophysiological roles of peroxynitrite in circulatory shock. *Shock.* 2010;34 Suppl 1(01):4–14. doi:10.1097/SHK.0b013e3181e7e9ba
57. Sang J, Chen Y, Tao Y. Nitric oxide inhibits gastric cancer cell growth through the modulation of the Akt pathway. *Mol Med Rep.* 2011;4(6):1163–1167. doi:10.3892/mmr.2011.535
58. Kielbik M, Klink M, Brzezinska M, Szulc I, Sulowska Z. Nitric oxide donors: spermine/NO and diethylenetriamine/NO induce ovarian cancer cell death and affect STAT3 and AKT signaling proteins. *Nitric Oxide.* 2013;35:93–109. doi:10.1016/j.niox.2013.09.001
59. Zhang J-Y, Zhang F, Hong C-Q, et al. Critical protein GAPDH and its regulatory mechanisms in cancer cells. *Cancer Biol Med.* 2015;12(1):10–22. doi:10.7497/j.issn.2095-3941.2014.0019
60. Pacher P, Szabo C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. *Am J Pathol.* 2008;173(1):2–13. doi:10.2353/ajpath.2008.080019
61. Klimiuk A, Zalewska A, Knapp M, Sawicki R, Ładny JR, Maciejczyk M. Salivary gland dysfunction in patients with chronic heart failure is aggravated by nitrosative stress, as well as oxidation and glycation of proteins. *Biomolecules.* 2021;11(1):1–27. doi:10.3390/biom11010119
62. Rashid M, Zadeh LR, Baradaran B, et al. Up-down regulation of HIF-1 α in cancer progression. *Gene.* 2021;798:145796. doi:10.1016/j.gene.2021.145796
63. Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. *Chem Biol Interact.* 2006;160(1):1–40. doi:10.1016/j.cbi.2005.12.009
64. Movafagh S, Crook S, Vo K. Regulation of hypoxia-inducible factor-1 α by reactive oxygen species: new developments in an old debate. *J Cell Biochem.* 2015;116(5):696–703. doi:10.1002/jcb.25074
65. Li F, Sonveaux P, Rabbani ZN, et al. Regulation of HIF-1 α Stability through S-Nitrosylation. *Mol Cell.* 2007;26(1):63–74. doi:10.1016/j.molcel.2007.02.024
66. Metzen E, Zhou J, Jelkmann W, Fandrey J, Brüne B. Nitric oxide impairs normoxic degradation of HIF-1 α by inhibition of prolyl hydroxylases. *Mol Biol Cell.* 2003;14(8):3470–3481. doi:10.1091/mbc.e02-12-0791
67. Paul SAM, Simons JW, Mabeesh NJ. HIF at the crossroads between ischemia and carcinogenesis. *J Cell Physiol.* 2004;200(1):20–30. doi:10.1002/jcp.10479
68. Thomas DD, Espey MG, Ridnour LA, et al. Hypoxic inducible factor 1 α , extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. *Proc Natl Acad Sci U S A.* 2004;101(24):8894–8899. doi:10.1073/pnas.0400453101
69. Thomas DD, Espey MG, Pociask DA, Ridnour LA, Donzelli S, Wink DA. Asbestos redirects nitric oxide signaling through rapid catalytic conversion to nitrite. *Cancer Res.* 2006;66(24):11600LP-11604. doi:10.1158/0008-5472.CAN-06-1140
70. Thomas DD, Ridnour LA, Isenberg JS, et al. The chemical biology of nitric oxide: implications in cellular signaling. *Free Radic Biol Med.* 2008;45(1):18–31. doi:10.1016/j.freeradbiomed.2008.03.020
71. Pena E, Brito J, El Alam S, Siques P. Oxidative stress, kinase activity and inflammatory implications in right ventricular hypertrophy and heart failure under hypobaric hypoxia. *Int J Mol Sci.* 2020;21(17):6421. doi:10.3390/ijms21176421
72. Hohensinner PJ, Kaun C, Rychli K, et al. Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. *FEBS Lett.* 2006;580(14):3532–3538. doi:10.1016/j.febslet.2006.05.043
73. Li X, Zhang Q, Nasser MI, et al. Oxygen homeostasis and cardiovascular disease: a role for HIF? *Biomed Pharmacother.* 2020;128:110338. doi:10.1016/j.biopha.2020.110338
74. Mil KM, Gryciuk ME, Pawlukianiec C, et al. Pleiotropic properties of Valsartan: do they result from the antiglycooxidant activity? Literature review and *in vitro* study. *Oxid Med Cell Longev.* 2021;2021:5575545. doi:10.1155/2021/5575545
75. Westra J, Brouwer E, Bos R, et al. Regulation of cytokine-induced HIF-1 α expression in rheumatoid synovial fibroblasts. *Ann N Y Acad Sci.* 2007;1108(1):340–348. doi:10.1196/annals.1422.035
76. Anna Z, Joanna K, Sara Z, et al. N-acetylcysteine supplementation did not reverse mitochondrial oxidative stress, apoptosis, and inflammation in the salivary glands of hyperglycemic rats. *Nutr Diabetes.* 2021;11(1):35. doi:10.1038/s41387-021-00177-w
77. Siraki AG, O'Brien PJ. Prooxidant activity of free radicals derived from phenol-containing neurotransmitters. *Toxicology.* 2002;177(1):81–90. doi:10.1016/S0300-483X(02)00197-X
78. Delporte M-L, Funahashi T, Takahashi M, Matsuzawa Y, Brichard SM. Pre- and post-translational negative effect of beta-adrenoceptor agonists on adiponectin secretion: *in vitro* and *in vivo* studies. *Biochem J.* 2002;367(Pt 3):677–685. doi:10.1042/BJ20020610
79. Letizia C, Petramala L, Di Gioia CRT, et al. Leptin and adiponectin mRNA expression from the adipose tissue surrounding the adrenal neoplasia. *J Clin Endocrinol Metab.* 2015;100(1):E101–E104. doi:10.1210/jc.2014-2274
80. Babinska A, Kaszubowski M, Sworczak K. Adipokine and cytokine levels in non-functioning adrenal incidentalomas (NFAI). *Endocr J.* 2018;65(8):849–858. doi:10.1507/endocrj.EJ18-0066

81. Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. *J Clin Invest*. 2001;108(12):1875–1881. doi:10.1172/JCI14120
82. Bin Rubaia'an MA, Alotaibi MK, Alotaibi NM, Alqhtani NR. Cortisol in oral and maxillofacial surgery: a double-edged sword. *Int J Dent*. 2021;2021:7642875. doi:10.1155/2021/7642875
83. Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-induced fatty liver disease. *Diabetes Metab Syndr Obes*. 2020;13:1133–1145. doi:10.2147/DMSO.S247379
84. Thuzar M, Stowasser M. The mineralocorticoid receptor—an emerging player in metabolic syndrome? *J Hum Hypertens*. 2021;35(2):117–123. doi:10.1038/s41371-020-00467-3
85. Arnaldi G, Scandali VM, Trementino L, Cardinaletti M, Appolloni G, Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. *Neuroendocrinology*. 2010;92(Suppl. 1):86–90. doi:10.1159/000314213
86. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004;89(6):2548–2556. doi:10.1210/jc.2004-0395

Journal of Inflammation Research

Dovepress

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular

mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>